Patient characteristics | Number | % |
Total evaluated | 101 | 100 |
Gender | Â | Â |
Male | 62 | 61 |
Female | 39 | 39 |
Median age (years range) | 63(26-80) | Â |
Performance Status | Â | Â |
0 | 79 | 78 |
1 | 20 | 20 |
>1 | 2 | 2 |
Primary tumor site | Â | Â |
Colon | 79 | 78 |
Rectum | 22 | 22 |
Liver metastases | 79 | 78 |
Number of metastatic sites | Â | Â |
1 | 77 | 76 |
>1 | 24 | 24 |
Previous chemotherapy lines | Â | Â |
0 | 43 | 42 |
1-2 | 40 | 40 |
>2 | 18 | 18 |
Median number of previous lines (range) | 2 (1-5) | Â |
Median interval time between first-line treatment and Cetuximab (months, range) | 18 (1-60) | Â |
Type of chemotherapy associatad with Cetuximab | Â | Â |
CPT-11 | 19 | 19 |
CPT-11, L-OHP, 5-FU | 29 | 29 |
FOLFIRI | 21 | 21 |
FOLFOX | 20 | 20 |
Only Cetuximab | 12 | 12 |